Antimicrobial polypeptides

J Leukoc Biol. 2004 Jan;75(1):34-8. doi: 10.1189/jlb.0403150. Epub 2003 Jul 15.

Abstract

The respiratory tract presents a large and potentially vulnerable surface to inhaled microbes. It is coated by a thin layer of secretions generated by airway epithelial cells, submucosal glands, resident and recruited phagocytes (neutrophils, eosinophils, monocytes, and macrophages) and alveolar epithelial cells, as well as substances that enter from blood plasma. More than 80 years ago, Alexander Fleming observed that respiratory secretions have microbicidal and microbistatic properties. He described the activity of lysozyme, one of the principal polypeptides of these secretions. Since then, a number of additional antimicrobial components have been identified, and there is increasing insight into their complex interactions. This review is an update of my previous summary of this area.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Antimicrobial Cationic Peptides / pharmacology
  • Antimicrobial Cationic Peptides / therapeutic use*
  • Humans
  • Muramidase / therapeutic use
  • Pulmonary Disease, Chronic Obstructive / drug therapy
  • Respiratory Mucosa / metabolism
  • Respiratory Tract Diseases / drug therapy*

Substances

  • Antimicrobial Cationic Peptides
  • Muramidase